PAVM — PAVmed Inc.

Summary of PAVmed Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Lucid's EsoGuard generated $1.2 million in revenue with over 2,800 tests conducted, consistent with prior quarters.
• Net Loss: PAVmed reported a GAAP net loss of $6 million, which includes a noncash loss of $4.4 million related to the change in fair value of equity investments. The non-GAAP loss was $446,000, reflecting ongoing development costs for the Veris implantable device.
• Cash Burn Rate: The company had a cash burn rate of $900,000 for the quarter, primarily due to operating costs and contractor development expenses.
• Balance Sheet: PAVmed's equity investment in Lucid was marked at $32 million as of September 30, reflecting a $4.4 million decrease due to stock price changes. PAVmed remains the largest shareholder of Lucid with a 23% ownership stake.

2. Strategic Updates and Business Highlights

• Corporate Restructuring: PAVmed has been stabilizing its corporate structure and balance sheet, successfully restructuring debt and deconsolidating Lucid from its financial statements.
• Lucid Diagnostics: The company is poised for Medicare coverage for EsoGuard, following a successful contractor meeting. Lucid raised approximately $27 million in a public offering, enhancing its financial position.
• Veris Digital Health: PAVmed launched the commercial phase of its partnership with Ohio State University (OSU) and is developing an implantable physiologic monitor, with an FDA submission planned for 2026.
• New Technology Development: PAVmed is finalizing a licensing agreement for an endoscopic imaging technology for esophageal pre-cancer, which is expected to enhance its product portfolio.

3. Forward Guidance and Outlook

• PAVmed anticipates that securing Medicare coverage for EsoGuard will significantly enhance its market position and revenue potential.
• The company plans to expand its commercial activities for Veris beyond OSU, leveraging lessons learned from the partnership and introducing clinical support services to enhance value for cancer centers.
• The development of the implantable device is on track, with a clear regulatory strategy in place, which should facilitate a straightforward path to FDA submission.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: PAVmed's ability to execute its broader vision has been constrained by capital market challenges and structural issues, although recent steps have improved its situation.
• Dependence on Lucid: While PAVmed has deconsolidated Lucid, its financial health remains tied to Lucid's performance, particularly as it is the largest shareholder.
• Operational Risks: The company faces operational challenges related to the development of new technologies and the need for effective commercialization strategies, particularly for Veris as it seeks to expand its market presence.

5. Notable Q&A Insights

• Implantable Monitor Development: The CEO clarified that the development of the implantable device is progressing well with a new manufacturing partner, and the clinical requirements for FDA submission are minimal.
• Commercialization Strategy: PAVmed plans to start commercialization discussions with other cancer centers in early 2026, leveraging the success of the OSU partnership and the addition of clinical support services.
• Endoscopic Imaging Technology: The licensing agreement for the new imaging technology is expected to be finalized soon, and it will initially be developed within a separate subsidiary before potential integration with Lucid.

Overall, PAVmed is navigating a transitional phase with positive developments in its core subsidiaries, but it must address ongoing market challenges and operational risks to realize its strategic vision.